Navigation Links
Aeterna Zentaris Reports Third Quarter 2010 Financial and Operating Results

Aeterna Zentaris Reports Third Quarter 2010 Financial and Operating Results

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Earnings Click to view news release full screen  

Aeterna Zentaris Reports Third Quarter 2010 Financial and Operating Results


QUEBEC CITY, Nov. 9 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS, TSX: AEZ) ("the Company") today reported financial and operating results for the third quarter ended September 30, 2010.

The Company's lead oncology compounds, perifosine, in Phase 3 registration trials for multiple myeloma and advanced colorectal cancer as well as in other earlier-stage cancer trials, and AEZS-108 in Phase 2 trials in advanced ovarian and endometrial cancer, continued to make significant progress.

"We are proud of the progress we have made over the last quarter as these products demonstrate our commitment to improving oncology treatment through 'personalized medicine'," said Juergen Engel, Ph.D., Aeterna Zentaris' President and Chief Executive Officer. "We now look forward to the presentation of Phase 2 results for AEZS-108 in advanced endometrial cancer at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics." Third Quarter 2010 Highlights (All amounts are in U.S. dollars)

  • Perifosine received orphan-drug designation by the United States Food and Drug Administration ("FDA") for the treatment of neuroblastoma, a cancer of the nervous system affecting mostly children and infants (July 14, 2010).
  • Dr. Jacek Pinski of the Norris Comprehensive Cancer Center awarded a grant from the National Institutes of Health ("NIH") for a Phase 1/2 study in advanced refractory prostate cancer with AEZS-108 (August 5, 2010).
  • An abstract on SolorelTM, an oral synthetic ghrelin receptor agonist currently in Phase 3 as a diagnostic test for Adult Growth Hormone Deficiency ("AGHD") was presented at the Seventh International Congress of Neuroendocrinology in Rouen, France. The data showed that Solorel's accuracy was at least equivalent to the current tests for AGHD (July 14, 2010).
  • Interim Phase 3 data on Solorel demonstrating the potential to provide a simple, well tolerated and safe oral diagnostic test for AGHD was also presented at the Fifth International Congress of the Growth Hormone Research Society and the Insulin-like Growth Factors Society in New York City (October 5, 2010).
  • "Our financial position continues to be solid with $39.9 million in cash and cash equivalents at quarter-end and a current controlled burn rate of approximately $2 million per month," said Dennis Turpin, Senior Vice President and Chief Financial Officer of Aeterna Zentaris. CONSOLIDATED RESULTS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2010Revenues were $5.7 million for the three-month period ended September 30, 2010, compared to $8.6 million for the same period in 2009. The decrease is due mainly to the absence, in 2010, of amortization of an upfront license fee payment related to our agreement with sanofi-aventis U.S. LLC, which was entered into in March 2009 and subsequently terminated, in connection with our now discontinued development program involving cetrorelix for the treatment of benign prostatic hyperplasia ("BPH"). Research and development ("R&D") costs, net of tax credits and grants, were $4.1 million for the three-month period ended September 30, 2010, compared to $9.7 million for the same period in 2009. The comparative decrease in net R&D costs is primarily attributable to the winding down and termination of development activities related to cetrorelix in BPH. Net losswas $10.1 million, or $0.12 per basic and diluted share, for the three-month period ended September 30, 2010, compared to $11.3 million, or $0.19 per basic and diluted share, for the same period in 2009. The decrease in net loss is attributable largely to lower net R&D expenses and to lower SG&A expenses, despite both the comparative decrease in revenues and the comparative increase in foreign exchange losses. Cash and cash equivalents totalled $39.9 million as at September 30, 2010. Conference call Management will be hosting a conference call for the investment community beginning at 4:00 p.m. Eastern Time today, Tuesday, November 9, 2010, to discuss third quarter 2010 results. Individuals interested in participating in the live conference call by telephone may dial, in Canada, 514-807-9895 or 647-427-7450, from outside Canada, 888-231-8191 or may listen through the Internet at in the Newsroom section. A replay will be available on the Company's website for 30 days following the live event. About Aeterna Zentaris Inc. Aeterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, ovarian and endometrial cancer as well as multiple myeloma. The Company's innovative approach of "personalized medicine" means tailoring treatments to a patient's specific condition and to unmet medical needs. Aeterna Zentaris' deep pipeline is drawn from its proprietary discovery unit providing constant and long-term access to state-of-the-art therapeutic options. For more information please visit Forward-Looking Statements This press release contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or by applicable law. Attachment: Financial summaryInterim Consolidated Results of Operations
    (in thousands, except for share and per share data)

        Three months ended
    September 30, Nine months ended
    September 30,   2010 2009 2010 2009   $ $ $ $ Revenues Sales and royalties 5,463 5,539 16,344 15,937 License fees and other 263 3,026 1,388 7,118   5,726 8,565 17,732 23,055 Operating expenses Cost of sales, excluding depreciation and amortization 4,292 4,488 13,324 12,727 Research and development costs, net of tax credits and grants 4,061 9,738 14,791 33,251 Selling, general and administrative expenses 2,859 3,193 8,780 9,849 Depreciation and amortization   Property, plant and equipment 239 341 744 983   Intangible assets 363 594 1,110 1,714   11,814 18,354 38,749 58,524 Loss from operations (6,088) (9,789) (21,017) (35,469) Other income (expenses) Interest income 22 39 111 311 Foreign exchange (loss) gain (4,081) (1,538) 429 (1,598)   (4,059) (1,499) 540 (1,287) Net loss for the period (10,147) (11,288) (20,477) (36,756)   Net loss per share Basic and diluted (0.12) (0.19) (0.28) (0.67) Weighted average number of shares Basic and diluted 83,139,620 58,506,619 73,122,927 55,135,876 Interim Consolidated Balance Sheet Information
    (in thousands)
    (unaudited)   As atSeptember 30,2010 As at
    December 31,
    2009   $ $ Cash and cash equivalents 39,866 38,100 Accounts receivable and other current assets 7,392 10,913 Restricted cash 841 878 Property, plant and equipment 3,357 4,358 Other long-term assets 29,404 32,013 Total assets 80,860 86,262 Accounts payable and other current liabilities 13,313 19,211 Current portion of long-term payable 58 57 Long-term payable 87 143 Non-financial long-term liabilities* 52,611 57,625 Total liabilities 66,069 77,036 Shareholders' equity 14,791 9,226 Total liabilities and shareholders' equity 80,860 86,262

    * Comprised mainly of deferred revenues and employee future benefits.

    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
    2. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
    3. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
    4. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
    5. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
    6. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
    7. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
    8. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
    9. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
    10. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
    11. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
    Post Your Comments:
    (Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ... hosting a Webinar titled, “Pathology is going digital. Is your lab ready?” with ... adoption best practices and how Proscia improves lab economics and realizes an increase ...
    (Date:10/11/2017)... Tampa Bay, Florida (PRWEB) , ... October 11, ... ... Food and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its ... antibody (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the ...
    (Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
    (Date:10/9/2017)... Jupiter, FL (PRWEB) , ... October 09, 2017 , ... ... episode, scheduled to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on ... Agriculture industry is faced with the challenge of how to continue to feed a ...
    Breaking Biology Technology:
    (Date:6/23/2017)... and ITHACA, N.Y. , June ... Cornell University, a leader in dairy research, today announced ... designed to help reduce the chances that the global ... onset of this dairy project, Cornell University has become ... Sequencing the Food Supply Chain, a food safety initiative ...
    (Date:5/6/2017)... May 5, 2017 RAM Group ... a new breakthrough in biometric authentication based on ... mechanical properties to perform biometric authentication. These new sensors ... material created by Ram Group and its partners. This ... transportation, supply chains and security. Ram Group is ...
    (Date:4/13/2017)... April 13, 2017 UBM,s Advanced Design and ... will feature emerging and evolving technology through its 3D ... will run alongside the expo portion of the event ... and demonstrations focused on trending topics within 3D printing ... and manufacturing event will take place June 13-15, 2017 at ...
    Breaking Biology News(10 mins):